Advertisement

Association Between Concurrent Use of Amiodarone and DOACs and Risk of Bleeding in Patients With Atrial Fibrillation

Published:November 04, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.10.031
      Amiodarone is a commonly used pharmacotherapy in patients with atrial fibrillation (AF), with a potential for drug-drug interactions with direct oral anticoagulants (DOACs). We aimed to assess the bleeding risk after co-prescription of amiodarone and DOACs among adults with AF. We conducted a population-based, nested case-control study in Ontario, Canada. The study population included all patients with AF aged >66 years on a DOAC between April 1, 2011 and March 31, 2018. Cases were patients admitted with major bleeding (index date). Controls were matched in a 2:1 ratio to cases. We categorized exposure to amiodarone before the index date as: (1) current users (amiodarone within 60 days), (2) past users (amiodarone within 61 to 140 days), and (3) unexposed (no amiodarone prescription or amiodarone prescription >140 days before index date). Conditional logistic regression models were used to examine the association between bleeding and amiodarone co-prescription. Among 86,679 patients with AF on a DOAC, we identified 2,766 cases (3.2%) admitted with major bleeding. The median age of patients with AF was 80 years (interquartile range 75 to 85); 48.3% were women. After multivariable adjustment, there was a significant association between major bleeding and current use of amiodarone (adjusted odds ratio 1.53; 95% confidence interval 1.24 to 1.89, p <0.001) but no significant association between major bleeding and past use of amiodarone (adjusted odds ratio 1.13, 95% confidence interval 0.76 to 1.68, p = 0.545) compared with the unexposed group. In conclusion, among older patients with AF on a DOAC, there was 53% increased odds of major bleeding with the current use of amiodarone.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lip GY
        • Kakar P
        • Watson T.
        Atrial fibrillation–the growing epidemic.
        Heart. 2007; 93: 542-543
        • Williams BA
        • Honushefsky AM
        • Berger PB.
        Temporal trends in the incidence, prevalence, and survival of patients with atrial fibrillation from 2004 to 2016.
        Am J Cardiol. 2017; 120: 1961-1965
        • Kornej J
        • Börschel CS
        • Benjamin EJ
        • Schnabel RB.
        Epidemiology of atrial fibrillation in the 21st Century: novel Methods and New Insights.
        Circ Res. 2020; 127: 4-20
        • Zhu J
        • Alexander GC
        • Nazarian S
        • Segal JB
        • Wu AW.
        Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010–2017.
        Pharmacotherapy. 2018; 38: 907-920
        • Hill K
        • Sucha E
        • Rhodes E
        • Carrier M
        • Garg AX
        • Harel Z
        • Hundemer GL
        • Clark EG
        • Knoll G
        • McArthur E
        • Sood MM.
        Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants.
        JAMA Intern Med. 2020; 180: 1052-1060
        • Di Minno A
        • Frigerio B
        • Spadarella G
        • Ravani A
        • Sansaro D
        • Amato M
        • Kitzmiller JP
        • Pepi M
        • Tremoli E
        • Baldassarre D.
        Old and new oral anticoagulants: food, herbal medicines and drug interactions.
        Blood Rev. 2017; 31: 193-203
        • Celikyurt I
        • Meier CR
        • Kühne M
        • Schaer B.
        Safety and interactions of direct oral anticoagulants with antiarrhythmic drugs.
        Drug Saf. 2017; 40: 1091-1098
        • Chang SH
        • Chou IJ
        • Yeh YH
        • Chiou MJ
        • Wen MS
        • Kuo CT
        • See LC
        • Kuo CF.
        Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation.
        JAMA. 2017; 318: 1250-1259
        • Fralick M
        • Juurlink DN
        • Marras T.
        Bleeding associated with coadministration of Rivaroxaban and clarithromycin.
        CMAJ. 2016; 188: 669-672
        • Perram J
        • Joseph J
        • Holloway C.
        Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals.
        BMJ Case Rep. 2015; 2015
        • Stöllberger C.
        Drug interactions with new oral anticoagulants in elderly patients.
        Expert Rev Clin Pharmacol. 2017; 10: 1191-1202
        • Stöllberger C
        • Finsterer J.
        Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs.
        Epilepsy Res. 2016; 126: 98-101
        • Voukalis C
        • Lip GY
        • Shantsila E.
        Drug-drug interactions of non-vitamin K oral anticoagulants.
        Expert Opin Drug Metab Toxicol. 2016; 12: 1445-1461
        • Hellwig T
        • Gulseth M.
        Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?.
        Ann Pharmacother. 2013; 47: 1478-1487
        • Shurrab M
        • Koh M
        • Jackevicius CA
        • Qiu F
        • Conlon M
        • Caswell J
        • Tu K
        • Austin PC
        • Ko DT.
        Prescribing of two potentially interacting cardiovascular medications in atrial fibrillation patients on direct oral anticoagulants.
        Int J Cardiol Heart Vasc. 2021; 34100788
        • Mar PL
        • Horbal P
        • Chung MK
        • Dukes JW
        • Ezekowitz M
        • Lakkireddy D
        • Lip GYH
        • Miletello M
        • Noseworthy PA
        • Reiffel JA
        • Tisdale JE
        • Olshansky B
        Gopinathannair R, from the American Heart Association Electrocardiography and Arrhythmias Committee of the Council of Clinical Cardiology. Drug Interactions Affecting Antiarrhythmic Drug Use.
        Circ Arrhythm Electrophysiol. 2022; 15e007955
        • Steffel J
        • Verhamme P
        • Potpara TS
        • Albaladejo P
        • Antz M
        • Desteghe L
        • Haeusler KG
        • Oldgren J
        • Reinecke H
        • Roldan-Schilling V
        • Rowell N
        • Sinnaeve P
        • Collins R
        • Camm AJ
        • Heidbuchel H
        • Group ESCSD
        The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
        Eur Heart J. 2018; 39: 1330-1393
        • Goto S
        • Zhu J
        • Liu L
        • Oh BH
        • Wojdyla DM
        • Aylward P
        • Bahit MC
        • Gersh BJ
        • Hanna M
        • Horowitz J
        • Lopes RD
        • Wallentin L
        • Xavier D
        • Alexander JH
        • Investigators ARISTOTLE
        Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the apixaban for Reduction in Stroke and Other thromboembolic events in atrial fibrillation (ARISTOTLE) trial.
        Am Heart J. 2014; 168: 303-309
        • Hori M
        • Connolly SJ
        • Zhu J
        • Liu LS
        • Lau CP
        • Pais P
        • Xavier D
        • Kim SS
        • Omar R
        • Dans AL
        • Tan RS
        • Chen JH
        • Tanomsup S
        • Watanabe M
        • Koyanagi M
        • Ezekowitz MD
        • Reilly PA
        • Wallentin L
        • Yusuf S
        • Investigators RE-LY
        Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
        Stroke. 2013; 44: 1891-1896
        • Shen AY
        • Yao JF
        • Brar SS
        • Jorgensen MB
        • Chen W.
        Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation.
        J Am Coll Cardiol. 2007; 50: 309-315
        • Wong KSL
        • Hu DY
        • Oomman A
        • Tan RS
        • Patel MR
        • Singer DE
        • Breithardt G
        • Mahaffey KW
        • Becker RC
        • Califf R
        • Fox KAA
        • Berkowitz SD
        • Hacke W
        • Hankey GJ.
        Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
        Stroke. 2014; 45: 1739-1747
      1. Thrombosis Canada. Clinical Guides. Available at: http://thrombosiscanada.ca/clinicalguides/#. Accessed on July 15, 2021.

        • Chen A
        • Stecker E
        • A Warden B
        Direct oral anticoagulant use: a practical guide to common clinical challenges.
        J Am Heart Assoc. 2020; 9e017559
        • Ko DT
        • Dattani ND
        • Austin PC
        • Schull MJ
        • Ross JS
        • Wijeysundera HC
        • Tu JV
        • Eberg M
        • Koh M
        • Krumholz HM.
        Emergency department volume and outcomes for patients after chest pain assessment.
        Circ Cardiovasc Qual Outcomes. 2018; 11e004683
        • Tu K
        • Nieuwlaat R
        • Cheng SY
        • Wing L
        • Ivers N
        • Atzema CL
        • Healey JS
        • Dorian P.
        Identifying patients with atrial fibrillation in administrative data.
        Can J Cardiol. 2016; 32: 1561-1565
        • Connolly SJ.
        Evidence-based analysis of amiodarone efficacy and safety.
        Circulation. 1999; 100: 2025-2034
        • Vassallo P
        • Trohman RG.
        Prescribing amiodarone: an evidence-based review of clinical indications.
        JAMA. 2007; 298: 1312-1322
        • Kannan R
        • Nademanee K
        • Hendrickson JA
        • Rostami HJ
        • Singh BN.
        Amiodarone kinetics after oral doses.
        Clin Pharmacol Ther. 1982; 31: 438-444
        • Letelier LM
        • Udol K
        • Ena J
        • Weaver B
        • Guyatt GH.
        Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis.
        Arch Intern Med. 2003; 163: 777-785
        • Connolly SJ
        • Ezekowitz MD
        • Yusuf S
        • Eikelboom J
        • Oldgren J
        • Parekh A
        • Pogue J
        • Reilly PA
        • Themeles E
        • Varrone J
        • Wang S
        • Alings M
        • Xavier D
        • Zhu J
        • Diaz R
        • Lewis BS
        • Darius H
        • Diener HC
        • Joyner CD
        • Wallentin L
        RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Flaker G
        • Lopes RD
        • Hylek E
        • Wojdyla DM
        • Thomas L
        • Al-Khatib SM
        • Sullivan RM
        • Hohnloser SH
        • Garcia D
        • Hanna M
        • Amerena J
        • Harjola VP
        • Dorian P
        • Avezum A
        • Keltai M
        • Wallentin L
        • Granger CB
        ARISTOTLE Committees and Investigators. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
        J Am Coll Cardiol. 2014; 64: 1541-1550
        • Granger CB
        • Alexander JH
        • McMurray JJ
        • Lopes RD
        • Hylek EM
        • Hanna M
        • Al-Khalidi HR
        • Ansell J
        • Atar D
        • Avezum A
        • Bahit MC
        • Diaz R
        • Easton JD
        • Ezekowitz JA
        • Flaker G
        • Garcia D
        • Geraldes M
        • Gersh BJ
        • Golitsyn S
        • Goto S
        • Hermosillo AG
        • Hohnloser SH
        • Horowitz J
        • Mohan P
        • Jansky P
        • Lewis BS
        • Lopez-Sendon JL
        • Pais P
        • Parkhomenko A
        • Verheugt FW
        • Zhu J
        • Wallentin L
        • ARISTOTLE Committees and Investigators
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Juurlink DN
        • Mamdani M
        • Kopp A
        • Laupacis A
        • Redelmeier DA.
        Drug-drug interactions among elderly patients hospitalized for drug toxicity.
        JAMA. 2003; 289: 1652-1658
        • Trikha R
        • Kowey PR.
        Practical considerations for the nonvitamin K antagonist oral anticoagulants.
        Cardiology. 2017; 136: 115-124